ISRG
67
-7
SLB
60
12
TROW
40
3
BXP
49
3
MAR
42
-2
LRCX
40
-2
STI
24
-2
AES
41
-2
DE
40
4
MDLZ
48
-2
AKAM
59
3
HOG
45
7
GPC
41
4
HAS
46
3
THC
73
3
FITB
69
3
ALLE
53
5
WU
24
4
WFC
71
2
TMO
59
-7
ISRG
67
-7
SLB
60
12
TROW
40
3
BXP
49
3
MAR
42
-2
LRCX
40
-2
STI
24
-2
AES
41
-2
DE
40
4
MDLZ
48
-2
AKAM
59
3
HOG
45
7
GPC
41
4
HAS
46
3
THC
73
3
FITB
69
3
ALLE
53
5
WU
24
4
WFC
71
2
TMO
59
-7
Financhill
Back

Kymera Therapeutics 10K Form

Buy
82

KYMR
Kymera Therapeutics

Last Price:
44.72
Seasonality Move:
-10.98%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KYMR News And Ratings

See the #1 stock for the next 7 days that we like better than KYMR

KYMR Financial Statistics

Sales & Book Value

Annual Sales: $78.59M
Cash Flow: $-46.99M
Price / Cash Flow: 0
Annual Sales: $11.59
Price / Book: 3.8

Profitability

EPS (TTM): -2.51000
Net Income (TTM): $-154.59M
Gross Margin: --
Return on Equity: -32.22%
Return on Assets: -24.21%

Kymera Therapeutics Earnings Forecast

Key Kymera Therapeutics Financial Ratios

  • The Research & Development expenses have been 240.59% of Revenue.
  • The Interest Expense is -0.13% of Operating Income.
  • The Net Earning history of KYMR is -186.99% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

Kymera Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: KYMR
Website: kymeratx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 9.57
Quick Ratio: 9.31

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

KYMR Technical Analysis vs Fundamental Analysis

Buy
82
Kymera Therapeutics (KYMR) is a Buy

Is Kymera Therapeutics a Buy or a Sell?